Gilead Sciences

This study tested a single daily pill containing four HIV medicines in 129 teens and children who either had never been treated or had their virus already under control. Researchers checked how the drug moved through the body, its safety, and how well it kept the virus in check. …

This study tested whether two drugs—semaglutide and a combination of cilofexor and firsocostat—could reduce liver scarring in people with cirrhosis caused by NASH. About 450 adults with compensated cirrhosis took one or both drugs or a placebo for 72 weeks. The goal was to see if…

This early-stage study tested two experimental vaccines, GS-2829 and GS-6779, in 83 healthy volunteers and people with chronic hepatitis B. The main goal was to see if the vaccines were safe and tolerable. Researchers also looked for signs that the vaccines boosted the immune sys…

This study checked the long-term safety of the drug sacituzumab govitecan in 25 people with metastatic solid tumors (cancer that has spread) who were already benefiting from the treatment. Researchers tracked side effects and lab abnormalities. The goal was to see how safe the dr…

This study tested whether a combination of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) is safe for women with HIV who are already on standard antiretroviral therapy (ART). The 20 participants were all women from a spe…

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check safety over 12 weeks. Results showed the oral pill was safe and well-tolerated, offering a convenient alte…

This study looked at how the liver processes the drug bulevirtide in 74 people with either normal or impaired liver function. Researchers measured drug levels in the blood and how long it takes the body to clear it. The goal was to understand dosing needs for patients with liver …

This study looked at how the drug bulevirtide behaves in the body of people with chronic hepatitis D who have normal or reduced kidney function. Researchers measured drug levels in the blood and checked safety over several doses. The goal was to understand how kidneys affect the …